Adam12 Antibody

What is ADAM12 and why is it important in cancer research?

ADAM12 (A Disintegrin And Metalloproteinase domain 12) is a member of the ADAM family of proteins involved in cell-cell and cell-matrix interactions. ADAM12 exists in two forms: a transmembrane long form (ADAM12L) and a secreted short form (ADAM12S) that lacks the transmembrane and cytoplasmic domains. The short form has been reported to provoke myogenesis, while different regulation pathways are suggested by the lack of cytoplasmic domain, although both forms can be expressed in the same tissue . ADAM12 has gained significant attention in cancer research due to its overexpression in various tumors, particularly in claudin-low triple-negative breast cancers, where it is upregulated through several pro-tumor signaling pathways including epithelial-to-mesenchymal transition (EMT), hypoxia, TGF-β, and Notch signaling .

How should I select an appropriate ADAM12 antibody for my specific research application?

When selecting an ADAM12 antibody, consider these key factors:

• Target specificity: Determine whether you need to detect total ADAM12 or distinguish between ADAM12L and ADAM12S.

• Species reactivity: Verify compatibility with your experimental model (human, mouse, rat).

• Validated applications: Confirm the antibody has been validated for your intended application (WB, IHC, IF/ICC, FC, IP).

• Reactivity profile: Review published literature and validation data showing the antibody's performance.

For example, antibody 14139-1-AP targets total ADAM12 and has been validated for WB, IHC, IF/ICC, FC (Intra), IP, and ELISA applications with demonstrated reactivity in human, mouse, and rat samples . When working across multiple applications, select antibodies with comprehensive validation data across your required techniques.

What are the optimal storage conditions for maintaining ADAM12 antibody activity?

Most ADAM12 antibodies require storage at -20°C in buffer solutions containing cryoprotectants. For instance, the 14139-1-AP antibody is supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 and should be stored at -20°C . Proper storage ensures antibody stability and prevents degradation that could compromise experimental results. Avoid repeated freeze-thaw cycles by preparing small working aliquots for routine use while maintaining the main stock at -20°C. When handling the antibody, always wear appropriate personal protective equipment due to the presence of sodium azide in many storage buffers.

What are the recommended dilutions for different applications of ADAM12 antibodies?

The optimal dilution varies by application and specific antibody. Based on validation data for antibody 14139-1-AP:

Important note: These dilutions should be optimized for each experimental system, as sample type, fixation method, and detection system can influence optimal antibody concentration . Preliminary titration experiments are strongly recommended before proceeding with critical experiments.

How should I optimize ADAM12 immunohistochemistry protocols for different tissue types?

For optimal ADAM12 detection in tissue sections, consider these methodological adjustments:

• Antigen retrieval: Begin with Tris-EDTA (TE) buffer at pH 9.0 as recommended for ADAM12 detection in human tissues. If results are suboptimal, citrate buffer pH 6.0 can be tested as an alternative .

• Tissue-specific considerations:

  • For breast cancer tissues: Different ADAM12 staining patterns have been observed across breast cancer subtypes. Infiltrating ductal carcinomas (IDC) show 47% positivity with mixed membrane and cytoplasmic localization, while infiltrating lobular carcinomas (ILC) show 97% positivity with predominantly cytoplasmic localization (92%) .

  • For non-tumorous terminal ductal lobular units (TDLU): These typically show 28% positivity with predominant membrane localization (60%) .

• Controls: Include both positive controls (placenta tissue or breast cancer samples) and negative controls to validate staining specificity .

The optimization process should involve systematic testing of different antigen retrieval methods, antibody dilutions, and incubation times to determine the protocol that yields specific staining with minimal background.

What molecular weight bands should I expect when using ADAM12 antibodies in Western blot analysis?

When performing Western blot analysis with ADAM12 antibodies, you should expect to observe bands at:

• 90-100 kDa: Corresponding to the full-length protein

• 70-80 kDa: Representing processed or alternative forms

The calculated molecular weight of ADAM12 is approximately 100 kDa, but post-translational modifications or proteolytic processing can result in multiple bands. The differential banding pattern may also reflect the presence of ADAM12L (long) versus ADAM12S (short) forms. When analyzing Western blot results, consider that sample preparation methods, reducing conditions, and gel percentage can all affect the apparent molecular weight. In publications, always specify which form(s) you are detecting to avoid misinterpretation of results.

How does ADAM12 expression vary across different breast cancer subtypes?

ADAM12 expression shows significant variation across breast cancer subtypes, as evidenced by extensive immunohistochemical analyses:

These data reveal that infiltrating lobular carcinomas (ILC) demonstrate nearly ubiquitous ADAM12 expression (97% positive) with intense staining (3.0/3.0) and predominantly cytoplasmic localization (92%). In contrast, infiltrating ductal carcinomas (IDC) show more modest expression (47% positive) with lower intensity (1.8/3.0) and variable subcellular localization . This differential expression pattern suggests distinct biological roles for ADAM12 across breast cancer subtypes and may have implications for using ADAM12 as a diagnostic or prognostic marker.

What is the relationship between ADAM12 expression and tumor-infiltrating immune cells?

Recent research has revealed critical relationships between ADAM12 expression and the tumor immune microenvironment:

• ADAM12 knockout in claudin-low triple-negative breast cancer (TNBC) models leads to:

  • Decreased numbers of tumor-infiltrating neutrophils (TINs)/polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs)

  • Increased numbers of tumor-infiltrating B cells and T cells

• Mechanistic studies demonstrate that:

  • ADAM12 loss in cancer cells increases B cell chemotaxis in vitro

  • This effect is eliminated by inhibition of CXCR4 (a receptor for CXCL12) or by anti-CXCL12 blocking antibody

• Therapeutic implications:

  • ADAM12 loss sensitizes tumors to anti-PD1/anti-CTLA4 combination therapy

  • B cell depletion eliminates the improved response to immune checkpoint blockade in Adam12 knockout tumors

These findings implicate ADAM12 in immunosuppression within the tumor microenvironment, particularly in TNBC. Analysis of gene expression data from the METABRIC patient cohort shows significant inverse correlations between ADAM12 and gene signatures of several anti-tumor immune cell populations, alongside a significant positive correlation between ADAM12 and gene signatures of TINs/PMN-MDSCs .

How can ADAM12 antibodies be used to differentiate between tumor and stromal expression?

Distinguishing between tumor cell and stromal cell expression of ADAM12 requires careful immunohistochemical analysis with appropriate controls. Studies have shown that approximately 63% of breast cancer cases exhibit positive ADAM12 immunoreactivity in tumor cells . This differentiation is methodologically important because:

• Cellular source impacts interpretation: ADAM12 produced by tumor cells versus stromal cells may have different biological implications.

• Staining pattern analysis:

  • Membrane staining is more common in certain subtypes (e.g., 42% in IDC)

  • Cytoplasmic staining predominates in others (e.g., 92% in ILC)

• Technical approach:

  • Use serial sections with epithelial markers (e.g., cytokeratins) to identify tumor cells

  • Consider dual immunofluorescence with epithelial/stromal markers

  • Analyze tissue microarrays with diverse cancer types to establish patterns

How can I address non-specific binding when using ADAM12 antibodies?

Non-specific binding is a common challenge when working with ADAM12 antibodies. To minimize this issue:

• Optimize blocking conditions:

  • Test different blocking agents (BSA, normal serum, commercial blocking solutions)

  • Extend blocking time to 1-2 hours at room temperature

  • Consider adding 0.1-0.3% Triton X-100 for better penetration in tissue sections

• Titrate primary antibody concentration:

  • Start with the manufacturer's recommended dilution range (e.g., 1:50-1:500 for IHC)

  • Perform systematic dilution series to identify optimal concentration

  • Remember that higher antibody concentrations often increase background

• Include appropriate controls:

  • Use ADAM12 knockout or knockdown samples as negative controls

  • Include secondary antibody-only controls to assess background

  • Consider isotype controls to evaluate non-specific binding

• Optimize washing steps:

  • Increase wash buffer volume and number of washes

  • Add 0.05-0.1% Tween-20 to wash buffers to reduce non-specific interactions

  • Extend washing times between antibody incubations

These methodological adjustments should be systematically tested and documented to establish a reliable protocol for your specific experimental system.

What are the critical variables that affect ADAM12 antibody performance in flow cytometry?

For optimal ADAM12 detection by flow cytometry, consider these technical factors:

• Cell preparation and fixation:

  • Fresh versus frozen cells may yield different results

  • Fixation method affects epitope accessibility (paraformaldehyde versus alcohol-based fixatives)

  • Permeabilization conditions must be optimized for intracellular staining

• Antibody concentration and incubation conditions:

  • For intracellular ADAM12 detection, use approximately 0.25 μg antibody per 10^6 cells in 100 μl suspension

  • Temperature and duration of antibody incubation affect staining intensity

  • Buffer composition (presence of serum, detergents) influences binding specificity

• Data acquisition and analysis considerations:

  • Set appropriate compensation when using multiple fluorophores

  • Use isotype controls to determine positive population thresholds

  • Consider cell size/complexity changes when analyzing ADAM12 expression in different cell populations

When troubleshooting flow cytometry experiments, change only one variable at a time and thoroughly document each modification to establish an optimized protocol.

How should I validate ADAM12 antibody specificity in my experimental system?

Rigorous validation of ADAM12 antibody specificity is essential for reliable research outcomes. Follow these methodological steps:

• Genetic validation:

  • Test antibody on ADAM12 knockout/knockdown samples

  • Use CRISPR-edited cells with specific gRNA vectors (e.g., 5'-GATGACCAAGTACGTAGAGC-3' or 5'-CCAAGGAACCACCATCGGCA-3')

  • Compare staining patterns before and after ADAM12 depletion

• Peptide competition assays:

  • Pre-incubate antibody with excess immunizing peptide

  • Perform parallel experiments with blocked and unblocked antibody

  • Loss of signal confirms specificity for the target epitope

• Multiple detection methods:

  • Correlate protein detection with mRNA expression

  • Use alternative antibodies targeting different ADAM12 epitopes

  • Compare results across different applications (WB, IHC, IF)

• Cross-reactivity assessment:

  • Test antibody on samples expressing related ADAMs

  • Verify species specificity if working across multiple models

  • Analyze tissues with known positive and negative ADAM12 expression

Document all validation steps in detail to support the reliability of your experimental findings and to facilitate reproducibility by other researchers.

How can ADAM12 antibodies be used to investigate its role in immune checkpoint blockade therapy?

Recent research has revealed that ADAM12 may influence responses to immune checkpoint blockade (ICB) therapy in cancer models. To investigate this relationship:

• Experimental design approaches:

  • Generate ADAM12 knockout/knockdown tumor models using CRISPR-Cas9 technology

  • Compare tumor growth and immune infiltration in wild-type versus ADAM12-deficient tumors

  • Combine with anti-PD1/anti-CTLA4 treatment to assess therapy response

• Immune profiling methodology:

  • Use flow cytometry with ADAM12 antibodies alongside immune cell markers

  • Perform multiplex immunohistochemistry to spatially resolve ADAM12 expression relative to immune cell infiltration

  • Analyze changes in immune cell populations before and after ICB therapy

• Mechanistic investigations:

  • Assess CXCL12/CXCR4 signaling axis using blocking antibodies or inhibitors

  • Perform B cell depletion experiments to evaluate their contribution to ICB responses

  • Conduct chemotaxis assays to measure immune cell recruitment

These approaches have revealed that ADAM12 loss sensitizes tumors to anti-PD1/anti-CTLA4 combination therapy, though initial responsiveness is often followed by acquired therapy resistance. B cell depletion eliminates the improved response to ICB observed in ADAM12 knockout tumors, highlighting a potential mechanistic pathway .

What are the implications of different subcellular localization patterns of ADAM12 in breast cancer?

The subcellular localization of ADAM12 varies significantly across breast cancer subtypes, with important functional implications:

This differential localization suggests distinct functions:

• Membrane-localized ADAM12 (predominant in normal TDLU and some IDC):

  • May facilitate cell-cell and cell-matrix interactions

  • Potentially involved in juxtacrine signaling mechanisms

  • Could mediate direct proteolytic processing of membrane-bound substrates

• Cytoplasmic-localized ADAM12 (predominant in ILC and carcinoma TDLU):

  • May represent internalized protein or newly synthesized pools

  • Could indicate altered trafficking or post-translational modification

  • Might reflect a functional shift in ADAM12 activity during malignant transformation

To investigate these patterns:

• Use subcellular fractionation followed by Western blotting

• Perform co-localization studies with organelle markers

• Assess correlation between localization and proteolytic activity

These localization differences may have prognostic implications and could inform therapeutic strategies targeting ADAM12 in breast cancer .

How does ADAM12 interact with other signaling pathways in the tumor microenvironment?

ADAM12 is involved in complex signaling networks within the tumor microenvironment through multiple mechanisms:

• Growth factor signaling modulation:

  • ADAM12 stimulates epidermal growth factor receptor (EGFR) signaling through shedding of membrane-bound ligands

  • It promotes TGF-β pathway activation, potentially through release of latent TGF-β from the extracellular matrix

  • ADAM12 enhances Notch signaling, influencing tumor cell stemness and differentiation

• Immune signaling interactions:

  • ADAM12 influences CXCL12/CXCR4 chemokine signaling, affecting B cell recruitment

  • It modulates the balance of immune cell populations, particularly decreasing B and T cell infiltration while increasing neutrophil/PMN-MDSC presence

  • Gene expression analysis shows inverse correlations between ADAM12 and signatures of anti-tumor immune cell populations

• Experimental approaches to investigate these interactions:

  • Perform co-immunoprecipitation with ADAM12 antibodies to identify binding partners

  • Use phospho-specific antibodies to assess activation of downstream signaling components

  • Conduct transcriptomic analysis comparing wild-type and ADAM12-deficient tumors

  • Employ pharmacological inhibitors of specific pathways to assess interdependence

Understanding these complex interactions is essential for developing combination therapies that target ADAM12 alongside other pathways to overcome immunosuppression in the tumor microenvironment.

What are emerging applications of ADAM12 antibodies in personalized cancer therapy?

ADAM12 antibodies are becoming increasingly valuable in personalized cancer medicine through several developing applications:

• Patient stratification:

  • ADAM12 expression correlates with specific breast cancer subtypes (particularly high in ILC at 97% positivity)

  • ADAM12 levels may predict response to immune checkpoint inhibitors

  • The protein's expression pattern (membrane vs. cytoplasmic) provides additional prognostic information

• Therapeutic targeting:

  • Inhibiting ADAM12 may enhance immune cell infiltration, particularly B and T cells

  • ADAM12 blockade could sensitize resistant tumors to existing immunotherapies

  • Combination approaches targeting both ADAM12 and the CXCL12/CXCR4 axis may provide synergistic benefits

• Monitoring treatment response:

  • ADAM12 antibodies can be used to assess changes in expression during therapy

  • Alterations in ADAM12 localization might indicate treatment effects

  • Dynamic changes in ADAM12 levels could serve as pharmacodynamic markers

Future research should focus on establishing standardized protocols for ADAM12 detection in clinical samples and correlating expression patterns with treatment outcomes in prospective clinical trials.

What are the key methodological challenges in studying ADAM12 in the tumor microenvironment?

Investigating ADAM12 in the complex tumor microenvironment presents several methodological challenges:

• Distinguishing cellular sources:

  • Differentiating between ADAM12 produced by tumor cells versus stromal cells requires sophisticated co-staining approaches

  • Single-cell analysis techniques may be needed to resolve cell type-specific expression patterns

  • Spatial relationships between ADAM12-expressing cells and immune populations are difficult to capture with traditional methods

• Functional assessment:

  • ADAM12's proteolytic activity may differ from its expression level

  • Developing activity-based probes for in situ ADAM12 functionality remains technically challenging

  • Distinguishing between ADAM12L and ADAM12S functions requires isoform-specific tools

• Dynamic regulation:

  • ADAM12 may be regulated post-translationally, requiring time-resolved studies

  • Its expression and activity might change during tumor progression or treatment

  • Capturing these dynamics necessitates sequential sampling approaches

Addressing these challenges will require combining advanced imaging technologies (multiplexed immunofluorescence, imaging mass cytometry), functional proteomics, and spatial transcriptomics to create integrated maps of ADAM12 activity within the tumor microenvironment.

How can researchers integrate ADAM12 data with broader immune profiling in cancer research?

Integrating ADAM12 analysis with comprehensive immune profiling offers powerful insights into cancer biology:

• Multi-parameter analytical approaches:

  • Combine ADAM12 antibody staining with panels of immune cell markers

  • Correlate ADAM12 expression with immune checkpoint molecules (PD-1, PD-L1, CTLA-4)

  • Assess relationships between ADAM12 levels and cytokine/chemokine profiles

• Computational integration strategies:

  • Apply gene set enrichment analysis to correlate ADAM12 with immune signatures

  • Use dimensionality reduction techniques to visualize relationships in high-dimensional data

  • Develop predictive models incorporating ADAM12 and immune parameters to forecast treatment response

• Translational research frameworks:

  • Establish tissue collection protocols that preserve both ADAM12 integrity and immune cell viability

  • Design clinical trials with integrated biomarker analyses including ADAM12

  • Create standardized reporting formats for ADAM12 and immune profiling data